STAAR-1 Clinical Study
Phase 4
Completed
- Conditions
- Chronic Kidney DiseaseChronic Renal InsufficiencyKidney DiseasePre-dialysisPre-ESRD
- Registration Number
- NCT00369772
- Lead Sponsor
- Amgen
- Brief Summary
To assess the effect of Aranesp on the hemoglobin of CRI subjects who are recombinant human erythropoetin (rHuEPO)-naïve or converting from rHuEPO therapy
- Detailed Description
To assess the effect of Aranesp on the hemoglobin of CRI subjectswho are recombinant human erythropoetin (rHuEPO)-naïve or converting from rHuEPO therapy and to assess the association between subject self-reported health-related quality of life (HRQoL) as it relates to Hgb concentration and glomerular filtration rate (GFR) in subjects who were rHuEPO-naïve prior to study enrollment. To characterize the health-related resource utilization of subjects with CRI. To characterize the subject satisfaction with Aranesp™ compared to previous rHuEPO therapy. To characterize iron treatment in subjects with CRI. To assess the safety profile of Aranesp™ therapy in subjects with CRI.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- ≥ 18 years old
- diagnosis of CRI and not receiving dialysis therapy (must be predialysis)
- measured or estimated (using the Cockcroft-Gault formula) creatinine clearance (CrCl) of ≤ 70 mL/min, or GFR ≤ 60 mL/min (using the MDRD formula):
- Cockcroft-Gault formula: CrCl = (140 minus age in years) x (body weight in kg) serum creatinine (mg/dL) x 72.0 For women, the value will be multiplied by 0.85
- MDRD formula: GFR = 170 x [SCr]-0.999 x [Age] -0.167 x [0.762 if subject is female] x [1.180 if subject is black] x [sun] -0.170SAlb]-0.318
- mean Hgb < 11 g/dL during the screening/baseline period (if subject is not already receiving rHuEPO therapy)
- for subjects currently receiving rHuEPO therapy, the subject must have: a stable rHuEPO dose for the past month; and a rHuEPO frequency of once weekly.
- white blood cell and platelet counts within normal limits
- serum vitamin B12 and folate levels above the lower limit of normal range
- transferrin saturation (TSAT) ≥ 20% during the screening period
- availability for follow-up assessments
- subject must be able to comprehend and be willing to, or have legally accepted representative, give written informed consent for participation in the study
Exclusion Criteria
- scheduled to initiate dialysis
- uncontrolled hypertension (diastolic blood pressure > 105 mm Hg or systolic blood pressure of > 180 mm Hg during the screening/baseline period on two separate measurements)
- clinically unstable in the judgment of the investigator (eg, subject is in the intensive care unit, immediately post-myocardial infarction, etc)
- scheduled to receive a living donor kidney transplant
- treatment of grand mal epilepsy within the past 6 months
- moderate to severe congestive heart failure (NYHA class III or IV)
- clinical evidence of severe secondary hyperparathyroidism (parathyroid hormone level > 1500 pg/mL)
- severe active chronic inflammatory process (eg, ulcerative colitis, peptic ulcer disease, rheumatoid arthritis, etc)
- currently receiving antibiotic therapy for systemic infection (enrollment may be postponed until the course of antibiotics has ended)
- known aspartate aminotransferase (AST) or alanine aminitransferase (ALT) greater than 3 times the upper limit of the normal range on more than one occasion within three months prior to screening
- known positive HIV antibody or hepatitis B surface antigen
- clinical evidence of current malignancy and/or receiving chemotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
- active bleeding or RBC transfusion within eight weeks of enrollment
- androgen therapy within four weeks before enrollment
- known hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma; hemolytic anemia, etc)
- any condition that is likely to affect subject compliance
- currently or previously (within 30 days) enrolled in investigational device or drug trial(s) or receiving investigational agent(s)
- the exception to this is if the subject was enrolled in another Aranesp™ or rHuEPO protocol
- pregnant or breast feeding women (women of child-bearing potential must be using contraceptive precautions)
- women planning to have a child during the study period
- known hypersensitivity to the active substance or any of the excipients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Mean hemoglobin during the evaluation period.
- Secondary Outcome Measures
Name Time Method Change in hemoglobin throughout the study HRQoL scores of rHuEPO-naïve subjects measured at baseline, week 12, week 24, and end of study Health-related resource utilization, measured every 4 weeks, throughout the study Patient satisfaction scores of subjects previously on rHuEPO therapy, measured at baseline and week 12 Iron requirement (dose, frequency, and route) of subjects during the study